BCL2 and follicular lymphoma: Strong expression of bcl‐2 and CD10 may suggest secondary cutaneous involvement by follicular lymphoma, and bcl‐2 expression in > 75% of cells may be associated with an increased risk of skin recurrence in PCFCL [44].